The amino acid, sold as a focus-and-alertness supplement, was linked to reduced life expectancy in men in a large genetic analysis — but researchers stress it doesn’t show supplements shorten life.
Medicines Discovery Catapult is funding Flip Therapeutics and Nascent Therapeutics — one reprogramming immune cells, the other restoring aging cells’ power plants.
In a 1,000-person trial across Latin America, structured exercise, diet, brain training and heart-health monitoring — with ongoing coaching — sharply outperformed basic health education.
Scientists mapped how dormant tumor cells shelter inside protective niches of immune and support cells — a hideout that may explain why cancer comes back years later.
Three lots of the hospital multi-dose vials are being pulled nationwide after reports of leaking, cracked containers and particulate contamination that could be life-threatening if injected.
Venetoclax, already used for blood cancers, pushed latently infected cells to die and cut the intact viral reservoir in SIV-infected macaques, with effects lasting months.
GTX-102 missed all its goals in a Phase 3 study for the rare disorder, wiping out a would-be blockbuster and pushing the company toward significant cost cuts.
Emerging from stealth, the startup uses a “jumping gene” and lipid nanoparticles to insert therapeutic genes inside the body — a non-viral bet amid mounting safety worries about viral vectors.
With two suppliers shutting down, the FDA is deploying regulatory tools to prevent a shortage of the intravenous nutrition that premature and critically ill babies depend on.
Tracking healthy adults with MRI for nearly two decades, researchers found structural brain changes at least seven years before amyloid plaques became visible on scans.
Backed by Paul Allen’s estate, the Allen Institute, UW and Fred Hutch are building open AI models to invent new biological parts — a bet on narrow, purpose-built AI over one-size-fits-all systems.
Novartis and Ionis’s pelacarsen dramatically lowered lipoprotein(a), a common inherited cardiovascular risk, yet failed to cut heart attacks, strokes or cardiac deaths in its pivotal trial.